Close

move up move left move right move bottom

MORE THAN 26 MILLION PEOPLE WORLDWIDE HAVE BEEN PRESCRIBED XARELTO® 1

AF = atrial fibrillation; DVT = deep vein thrombosis; PE = pulmonary embolism.
NASCAR® is a registered trademark of the National Association
for Stock Car Auto Racing, Inc.

 

Indications

 

IMPORTANT SAFETY INFORMATION

 

Indication and Important saftey Information

 

  • Reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF). There are limited data on the relative effectiveness of XARELTO® (rivaroxaban) and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well controlled.
  • Treatment of deep vein thrombosis (DVT).
  • Treatment of pulmonary embolism (PE).
  • Reduction in the risk of recurrence of DVT and of PE following initial 6 months treatment for DVT and/or PE.
  • Prophylaxis of DVT, which may lead to PE in patients undergoing knee replacement surgery.
  • Prophylaxis of DVT, which may lead to PE in patients undergoing hip replacement surgery.

References:

  1. Data on file. Based on Bayer Healthcare AG utilizing IMS MIDAS Database: Monthly Sales through Oct 2016.
  2. Data on file. Janssen Pharmaceuticals, Inc.